Bessemer Group Inc Travere Therapeutics, Inc. Transaction History
Bessemer Group Inc
- $61.6 Billion
- Q2 2025
A detailed history of Bessemer Group Inc transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Bessemer Group Inc holds 206 shares of TVTX stock, worth $3,586. This represents 0.0% of its overall portfolio holdings.
Number of Shares
206
Previous 206
-0.0%
Holding current value
$3,586
Previous $4,000
25.0%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding TVTX
# of Institutions
242Shares Held
102MCall Options Held
1.79MPut Options Held
540K-
Armistice Capital, LLC New York, NY8.87MShares$154 Million2.42% of portfolio
-
Black Rock Inc. New York, NY7.64MShares$133 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X07.53MShares$131 Million0.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.99MShares$104 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C34.8MShares$83.5 Million0.11% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.12B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...